NASDAQ:FATE

Fate Therapeutics (FATE) Stock Price, News & Analysis

Fate Therapeutics logo
$1.27 +0.02 (+1.60%)
Closing price 02/13/2025 04:00 PM Eastern
Extended Trading
$1.26 -0.01 (-0.39%)
As of 02/13/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fate Therapeutics Stock (NASDAQ:FATE)

Key Stats

Today's Range
$1.24
$1.28
50-Day Range
$1.21
$2.72
52-Week Range
$1.04
$8.83
Volume
1.51 million shs
Average Volume
1.89 million shs
Market Capitalization
$144.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
Consensus Rating
Hold

Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

FATE MarketRank™: 

Fate Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 267th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fate Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Fate Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.63) to ($1.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fate Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fate Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fate Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Fate Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.30% of the outstanding shares of Fate Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Fate Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Fate Therapeutics has recently increased by 1.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Fate Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Fate Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.30% of the outstanding shares of Fate Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Fate Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Fate Therapeutics has recently increased by 1.34%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Fate Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fate Therapeutics insiders have bought 2,848.53% more of their company's stock than they have sold. Specifically, they have bought $668,580.00 in company stock and sold $22,675.00 in company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Fate Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fate Therapeutics' insider trading history.
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

Springworks Therapeutics (SWTX) Gets a Buy from Barclays
My 2025 AI Blueprint
I first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blueprint. And I have something surprising to tell you about it … It doesn't include Nvidia.
Mersana Therapeutics (MRSN) Receives a Buy from TD Cowen
Protagonist Therapeutics (PTGX) Gets a Buy from TD Cowen
See More Headlines

FATE Stock Analysis - Frequently Asked Questions

Fate Therapeutics' stock was trading at $1.65 on January 1st, 2025. Since then, FATE shares have decreased by 23.0% and is now trading at $1.27.
View the best growth stocks for 2025 here
.

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.02. The biopharmaceutical company earned $3.07 million during the quarter, compared to analysts' expectations of $0.88 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative trailing twelve-month return on equity of 45.88%.

Fate Therapeutics' top institutional investors include Vanguard Group Inc. (9.07%), Geode Capital Management LLC (1.96%), JPMorgan Chase & Co. (1.47%) and Walleye Capital LLC (0.95%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, Bahram Valamehr, John Mendlein, Jerome Charles Bressi, Cindy Tahl, Yu-Waye Chu, Mark Plavsic, Edward J Dulac III, Brian T Powl and Yuan Xu.
View institutional ownership trends
.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

Last Earnings
11/12/2024
Today
2/13/2025
Next Earnings (Estimated)
2/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
550
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.75
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+431.5%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$-160,930,000.00
Net Margins
-1,325.43%
Pretax Margin
-1,325.43%

Debt

Sales & Book Value

Annual Sales
$63.53 million
Book Value
$3.74 per share

Miscellaneous

Free Float
108,199,000
Market Cap
$144.64 million
Optionable
Optionable
Beta
2.02

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:FATE) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners